Genotype–phenotype correlation for extracolonic aggressive phenotypes in patients with familial adenomatous polyposis
Cancer Science · 2023
DOI: 10.1111/cas.15945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Yusaku Shimamoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Desmoid Tumors, Adenomatous Polyposis Coli, Stomach Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Familial adenomatous polyposis (FAP) patients develop various life‐threatening extracolonic comorbidities that appear individually or within a family. This diversity can be explained by the localization of the adenomatous polyposis coli ( APC ) variant, but few reports provide definitive findings about genotype–phenotype correlations. Therefore, we investigated FAP patients and the association between the severe phenotypes and APC variants. Of 247 FAP patients, 126 patients from 85 families identified to have APC germline variant sites were extracted. These sites were divided into six groups (Regions A to F), and the frequency of severe comorbidities was compared among the patient phenotypes. Of the 126 patients, the proportions of patients with desmoid tumor stage ≥III, number of FGPs ≥1000, multiple gastric neoplasms, gastric neoplasm with high‐grade dysplasia, and Spigelman stage ≥III were 3%, 16%, 21%, 12%, and 41%, respectively, while the corresponding rates were 30%, 50%, 70%, 50%, and 80% in patients with Region E (codons 1398–1580) variants. These latter rates were significantly higher than those for patients with variants in other regions. Moreover, the proportion of patients with all three indicators (desmoid tumor stage ≥III, number of FGPs ≥1000, and Spigelman stage ≥III) was 20% for those with variants in Region E and 0% for those with variants in other regions. Variants in Region E indicate aggressive phenotypes, and more intensive management is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Genetic Oncology, Division of Hereditary Tumors, Osaka International Cancer Institute, Osaka, Japan.
- Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
- PCL Osaka Pathology and Cytology Center, Osaka, Japan.
- Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.
- Ishikawa Gastroenterology Clinic, Osaka, Japan.
ORCID-Profile: Yusaku Shimamoto, Yoji Takeuchi, Tetsuji Takayama
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Shimamoto, Y., Takeuchi, Y., Ishiguro, S., Nakatsuka, S. I., Yunokizaki, H., Ezoe, Y., Nakajima, T., Tanaka, K., Ishihara, R., Takayama, T., Yoshida, T., Sugano, K., Mutoh, M., & Ishikawa, H. (2023). Genotype–phenotype correlation for extracolonic aggressive phenotypes in patients with familial adenomatous polyposis. Cancer Science. https://doi.org/10.1111/cas.15945
Vancouver
Shimamoto Y, Takeuchi Y, Ishiguro S, Nakatsuka SI, Yunokizaki H, Ezoe Y, et al. Genotype–phenotype correlation for extracolonic aggressive phenotypes in patients with familial adenomatous polyposis. Cancer Science. 2023. doi:10.1111/cas.15945
BibTeX
@article{Shimamoto2023,
author = {Shimamoto, Yusaku and Takeuchi, Yoji and Ishiguro, Shingo and Nakatsuka, Shin-Ichi and Yunokizaki, Hiroshi and Ezoe, Yasumasa and Nakajima, Takeshi and Tanaka, Kumiko and Ishihara, Ryu and Takayama, Tetsuji and Yoshida, Teruhiko and Sugano, Kokichi and Mutoh, Michihiro and Ishikawa, Hideki},
title = {Genotype–phenotype correlation for extracolonic aggressive phenotypes in patients with familial adenomatous polyposis},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15945}
}
EUVIMED